AV Troitsky*, IY Deulin, LB Kim, AN Putyatina, VG Selyatitskaya and MI Voevoda

Federal Research Centre for Fundamental and Translational Medicine, Novosibirsk, Russia

*Corresponding Author: AV Troitsky, Federal Research Centre for Fundamental and Translational Medicine, Novosibirsk, Russia.

Received: March 17, 2025; Published: April 16, 2025

Abstract

For the prevention of stroke, myocardial infarction, metabolic syndrome, and type II diabetes, biologically active dietary supplements containing plant extracts are among the most promising options. These dietary supplements can be used from the age of 25-30, as they are safe and do not exhibit significant dose-dependent side effects. The key aspect of developing such a biologically active dietary supplement is selecting the most effective plant extracts that, on one hand, provide mild hypoglycemic and hypocholesterolemic effects and moderately lower blood pressure, while on the other hand, ensure that their effects remain within the physiological norm for a healthy individual. To achieve this, a dietary supplement composition was developed based on plant extracts from Bergamot fruit, Wild Yam, Barberry fruit, and Peruvian Maca. This phytocomposition was formulated based on existing data on the physiological effects of these plant extracts. Considering the primary and additional activities of the components in the developed dietary supplement, it may provide comprehensive preventive effects against various age-related pathological processes.

 Keywords: Prevention; Biologically Active Dietary Supplement; Plant Extracts; Bergamot; Wild Yam; Barberry; Peruvian Maca

References

1. Gems D. “What is an anti-aging treatment?” Experimental Gerontology 58 (2014): 14-18.
2. Sayer AA., et al. “Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg?” Diabetes Care10 (2005): 2541-2542.
3. Li Z., et al. “Aging and age-related diseases: from mechanisms to therapeutic strategies”. Biogerontology2 (2021): 165-187.
4. Global Burden of Disease Study 2013 Collaborators. “Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990—2013: a systematic analysis for the Global Burden of Disease Study 2013”. Lancet 9995 (2015): 743-800.
5. Krishnamurthi RV., et al. “Stroke Prevalence, Mortality and Disability-Adjusted Life Years in Adults Aged 20—64 Years in 1990—2013: Data from the Global Burden of Disease 2013 Study”. Neuroepidemiology3 (2015): 190-202.
6. Emberson J., et al. “Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease”. European Heart Journal6 (2014): 484-491.
7. Nauman MC and Johnson JJ. “Clinical application of bergamot (Citrus bergamia) for reducing high cholesterol and cardiovascular disease markers”. Integrative Food, Nutrition and Metabolism 2 (2019): 1000249.
8. Gliozzi M., et al. “Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia”. International Journal of Cardiology2 (2013): 140-145.
9. Di Folco U., et al. “Effects of a nutraceutical multicompound including bergamot (Citrus bergamia Risso) juice on metabolic syndrome: a pilot study”. Mediterranean Journal of Nutrition and Metabolism 11 (2018): 119-126.
10. Musolino V., et al. “The effect of bergamot polyphenolic fraction on lipid transfer protein system and vascular oxidative stress in a rat model of hyperlipemia”. Lipids in Health and Disease 1 (2019): 115.
11. Della Vedova L., et al. “Chemical, nutritional and biological evaluation of a sustainable and scalable complex of Phytochemicals from bergamot by-products”. Molecules7 (2023): 2964. 
12. Siqueira JS., et al. “Overview of bergamot leaves extract (Citrus bergamia) effect on the RedOx/Inflammatory scenario in obesity target organs in an animal model of metabolic syndrome”. Journal of Functional Foods21 (2024): 106042.
13. Saghir SAM., et al. “The ameliorative effect of bergamot oil nano-emulsion in stressed rabbit bucks: influence on blood biochemical parameters, redox status, immunity indices, inflammation markers, semen quality, testicular changes and the expression of HSPs genes”. Saudi Pharmaceutical Journal 8 (2023): 101691.
14. Russo C., et al. “Bergamot byproducts: a sustainable source to counteract inflammation”. Nutrients2 (2024): 259.
15. Marrelli M., et al. “Effects of saponins on lipid metabolism: a review of potential health benefits in the treatment of obesity”. Molecules 10 (2016): 1404.
16. Zeng Q., et al. “Review of saponins in treating heart failure”. SciBase Epidemiology Public Health2 (2024): 1022.
17. Xiang Q., et al. “Neuroprotective effects of Rhizoma Dioscoreae polysaccharides against neuronal apoptosis induced by in vitro hypoxia”. Experimental and Therapeutic Medicine 6 (2015): 2063-2070.
18. Li SN., et al. “Anti‐obesity effectsexerted Dioscorea opposita polysaccharides in diet‐induced obese mice”. Food Science and Nutrition 11.10 (2023): 6459-6469. 
19. Kwon CS., et al. “Anti-obesity effect of Dioscorea nipponica Makino with lipase-inhibitory activity in rodents”. Bioscience, Biotechnology, and Biochemistry7 (2003): 1451-1456.
20. Ikete P and Chinko B. “Inhibition of serum lipase as a mechanism of action for anti-obesity potentials of Dioscorea bulbifera extracts on Wistar rats”. Asian Journal of Health Sciences 1 (2022): 29.
21. Tikhonova MA., et al. “Improving bone microarchitecture in aging with diosgenin treatment: a study in senescence-accelerated OXYS rats”. Chinese Journal of Physiology 5 (2015): 322-331.
22. Iemitsu K., et al. “Dioscorea esculenta intake with resistance training improves muscle quantity and quality in healthy middle-aged and older adults: a randomized controlled trial”. Nutrients11 (2023): 2438.
23. Sato K., et al. “Acute administration of diosgenin or dioscorea improves hyperglycemia with increases muscular steroidogenesis in STZ-induced type 1 diabetic rats”. The Journal of Steroid Biochemistry and Molecular Biology 143 (2014): 152-159.
24. Malik H., et al. “Diosgenin normalization of disrupted behavioral and central neurochemical activity after single prolonged stress”. Frontiers in Pharmacology14 (2023): 1232088.
25. Zarei A., et al. “A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L”. Avicenna Journal of Phytomedicine6 (2015): 485-497.
26. Imenshahidi M and Hosseinzadeh H. “Berberineand barberry (Berberis vulgaris): A clinical review”. Phytotherapy Research3 (2019): 504-523.
27. Kavyani Z., et al. “The effect of berberine supplementation on lipid profile and obesity indices: An umbrella review of meta-analysis”. Pharma Nutrition 26 (2023): 100364.
28. Hu Y., et al. “Berberine inhibits SREBP-1-related clozapine and risperidone induced adipogenesis in 3T3-L1 cells”. Phytotherapy Research12 (2010): 1831-1838.
29. Hadi A., et al. “Barberry (Berberis vulgaris ) is a safe approach for management of lipid parameters: A systematic review and meta-analysis of randomized controlled trials”. Complementary Therapies in Medicine 43 (2019): 117-124.
30. Shidfar F., et al. “The effects of Berberis vulgaris fruit extract on serum lipoproteins, apoB, apoA-I, homocysteine, glycemic control and total antioxidant capacity in type 2 diabetic patients”. Iranian Journal of Pharmaceutical Sciences 2 (2012): 643-652.
31. Zilaee M., et al. “Barberry treatment reduces serum anti-heat shock protein 27 and 60 antibody titres and high-sensitivity c-reactive protein in patients with metabolic syndrome: a double-blind, randomized placebo-controlled trial”. Phytotherapy Research8 (2014): 1211-1215.
32. Shakeri F., et al. “Anti-inflammatory, antioxidant, and immunomodulatory effects of Berberis vulgaris and its constituent berberine, experimental and clinical, a review”. Phytotherapy Research 4 (2024): 1882-1902.
33. Kavyani Z., et al. “The effect of berberine supplementation on lipid profile and obesity indices: An umbrella review of meta-analysis”. Pharma Nutrition 26 (2023): 100364.
34. Brusq JM., et al. “Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine”. Journal of Lipid Research6 (2006): 1281-1288.
35. Mi J., et al. “Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats”. Diabetes, Metabolic Syndrome and Obesity 12 (2019): 1717-1725.
36. Pérez-Rubio KG., et al. “Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion”. Metabolic Syndrome and Related Disorders 5 (2013): 366-369.
37. Zhang XY., et al. “The combination of berberine and isoliquiritigenin synergistically improved adipose inflammation and obesity-induced insulin resistance”. Phytotherapy Research 8 (2024): 3839-3855.
38. Moazezi Z and Qujeq D. “Berberis fruit extract and biochemical parameters in patients with type II diabetes”. Jundishapur Journal of Natural Pharmaceutical Products 2 (2014): e13490.
39. Yadawa AK., et al. “Berberine may provide redox homeostasis during aging in rats”. Zeitschrift für Naturforschung C 7-8 (2023): 307-315.
40. Yadawa AK., et al. “Berberine may provide redox homeostasis during aging in rats”. Zeitschrift für Naturforschung C7-8 (2023): 307-315.
41. Kermani T., et al. “The effect of Berberis vulgaris (barberry fruit) on a component of metabolic syndrome: a randomized clinical trial”. Modern Care Journal2 (2020): e93955.
42. Emamat H., et al. “The effect of barberry (Berberis vulgaris) consumption on flow-mediated dilation and inflammatory biomarkers in patients with hypertension: A randomized controlled trial”. Phytotherapy Research 5 (2021): 2607-2615.
43. Samadi P., et al. “Berberine: a novel therapeutic strategy for cancer”. IUBMB Life10 (2020): 2065-2079.
44. El-Zahar KM., et al. “Antioxidant, antibacterial, and antifungal activities of the ethanolic extract obtained from Berberis vulgaris roots and leaves”. Molecules18 (2022): 6114.
45. Peng L., et al. “Antibacterial activity and mechanism of berberine against Streptococcus agalactiae”. International Journal of Clinical and Experimental Pathology 5 (2015): 5217-5223.
46. Warowicka A., et al. “Antiviral activity of berberine”. Archives of Virology 9 (2020): 1935-1945.
47. Mohammadzadeh N., et al. “Berberis vulgaris and its constituent berberine as antidotes and protective agents against natural or chemical toxicities”. Iranian Journal of Basic Medical Sciences 5 (2017): 538-551. 
48. Zhu F and Qian C. “Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease”. BMC Neuroscience 7 (2006):
49. Zhang Q., et al. “Berberine preconditioning protects neurons against ischemia via sphingosine-1-phosphate and hypoxia-inducible factor-1α”. The American Journal of Chinese Medicine 5 (2016): 927-941.
50. Lee B., et al. “Berberine alleviates symptoms of anxiety by enhancing dopamine expression in rats with post-traumatic stress disorder”. The Korean Journal of Physiology and Pharmacology 2 (2018): 183-192.
51. Tan XS., et al. “Tissue distribution of berberine and its metabolites after oral administration in rats”. PLoS One10 (2013): e77969.
52. Dokkedal-Silva V., et al. “The increasing popularity of Peruvian maca (Lepidium meyenii) and its potential impacts on sleep and quality of life”. Clinics (Sao Paulo) 79 (2024):
53. Bower-Cargill C., et al. “A systematic review of the versatile effects of the Peruvian maca root (Lepidium meyenii) on sexual dysfunction, menopausal symptoms and related conditions”. Phytomedicine Plus4 (2022): 100326.
54. Valentová K., et al. “The in vitro biological activity of Lepidium meyenii extracts”. Cell Biology and Toxicology 2 (2006): 91-99.
55. Yoshida K., et al. “Long-term feeding of hydroalcoholic extract powder of Lepidium meyenii (maca) enhances the steroidogenic ability of Leydig cells to alleviate its decline with ageing in male rats”. Andrologia1 (2018).
56. Shin D., et al. “Efficacy and safety of Maca (Lepidium meyenii) in patients with symptoms of late-onset hypogonadism: a randomized, double-blind, placebo-controlled clinical trial”. The World Journal of Men s Health 3 (2023): 692-700.
57. Zhu H., et al. “Anti-fatigue effect of Lepidium meyenii Walp. (Maca) on preventing mitochondria-mediated muscle damage and oxidative stress in vivo and vitro”. Food Function 12.7 (2021): 3132-3141.
58. Arita J and Hirao K. “Cosmetic compositions containing papain-treated papaya and maca powders”. 2003: Japanese Patent 2 003 155 213 (2003).
59. Zha S., et al. “Extraction, purification and antioxidant activities of the polysaccharides from maca (Lepidium meyenii)”. Carbohydrate Polymers 111 (2014): 584-587.
60. Radák Z., et al. “Exercise training decreases DNA damage and increases DNA repair and resistance against oxidative stress of proteins in aged rat skeletal muscle”. Pflügers Archiv 2 (2002): 273-278.
61. Sun Y., et al. “Composition analysis and antioxidant activity of essential oils, lipids and polysaccharides in different phenotypes of Lepidium meyenii”. Journal of Chromatography B 1099 (2018): 25-33.
62. Kasprzak D., et al. “Lepidium peruvianumas a source of compounds with anticancer and cosmetic applications”. International Journal of Molecular Sciences19 (2024): 10816.
63. Zhang M., et al. “Structural сharacterization and immunomodulatory activity of a novel polysaccharide from Lepidium meyenii”. Journal of Agricultural and Food Chemistry 9 (2016): 1921-1931.
64. Valerio LG., et al. “Toxicological aspects of the South American herbs cat's claw (Uncaria tomentosa) and maca (Lepidium meyenii): a critical synopsis”. Toxicology Review 1 (2005): 11-35.
65. Xie JH., et al. “Advances on bioactive polysaccharides from medicinal plants”. Critical Reviews in Food Science and Nutrition 56 (2016): S60-S84.
66. Ren L., et al. “Antitumor activity of mushroom polysaccharides: a review”. Food Function11 (2012): 1118-1130.
67. Ferrarese I., et al. “Bergamot (Citrus bergamia) peel extract as new hypocholesterolemic agent modulating PCSK9 expression”. Journal of Functional Foods 108 (2023): 105724.
68. Sun F., et al. “The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review”. Diabetes, Metabolic Syndrome and Obesity 14 (2021): 4015-4030.
69. Fahadnejad H., et al. “Herbal Products as Complementary or Alternative Medicine for the Management of Hyperglycemia and Dyslipidemia in Patients with Type 2 Diabetes: Current Evidence Based on Findings of Interventional Studies”. Journal of Nutrition and Metabolism (2024).
70. Peres NSL., et al. “Medicinal effects of Peruvian maca (Lepidium meyenii): a review”. Food Function 11 (2020): 83-92.

Citation

Citation: AV Troitsky., et al. “Pathophysiological Approach to the Development of Plant Compositions with 'Anti-Age' Activity”.Acta Scientific Medical Sciences 9.5 (2025): 119-133.

Copyright

Copyright: © 2025 AV Troitsky., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.